{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(44)"],"submitter":["Gay-Bellile M"],"pubmed_abstract":["Upregulation of the telomerase reverse transcriptase (<i>TERT</i>) gene in human cancers leads to telomerase activation, which contributes to the growth advantage and survival of tumor cells. Molecular mechanisms of <i>TERT</i> upregulation are complex, tumor-specific and can be clinically relevant. To investigate these mechanisms in breast cancer, we sequenced the <i>TERT</i> promoter, evaluated <i>TERT</i> copy number changes and assessed the expression of the <i>MYC</i> oncogene, a known transcriptional <i>TERT</i> regulator, in two breast cancer cohorts comprising a total of 122 patients. No activating <i>TERT</i> promoter mutations were found, suggesting that this mutational mechanism is not likely to be involved in <i>TERT</i> upregulation in breast cancer. The T349C promoter polymor"],"journal":["Oncotarget"],"pagination":["77540-77551"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5652798"],"repository":["biostudies-literature"],"pubmed_title":["<i>TERT</i> promoter status and gene copy number gains: effect on <i>TERT</i> expression and association with prognosis in breast cancer."],"pmcid":["PMC5652798"],"pubmed_authors":["Bignon YJ","Combes P","Tchirkov A","Cayre A","Abrial C","Vago P","Dauplat MM","Privat M","Eymard-Pierre E","Penault-Llorca F","Gay-Bellile M","Kwiatkowski F","Mouret-Reynier MA","Veronese L"],"additional_accession":[]},"is_claimable":false,"name":"<i>TERT</i> promoter status and gene copy number gains: effect on <i>TERT</i> expression and association with prognosis in breast cancer.","description":"Upregulation of the telomerase reverse transcriptase (<i>TERT</i>) gene in human cancers leads to telomerase activation, which contributes to the growth advantage and survival of tumor cells. Molecular mechanisms of <i>TERT</i> upregulation are complex, tumor-specific and can be clinically relevant. To investigate these mechanisms in breast cancer, we sequenced the <i>TERT</i> promoter, evaluated <i>TERT</i> copy number changes and assessed the expression of the <i>MYC</i> oncogene, a known transcriptional <i>TERT</i> regulator, in two breast cancer cohorts comprising a total of 122 patients. No activating <i>TERT</i> promoter mutations were found, suggesting that this mutational mechanism is not likely to be involved in <i>TERT</i> upregulation in breast cancer. The T349C promoter polymor","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Sep","modification":"2026-04-29T09:53:45.003Z","creation":"2019-03-27T02:59:41Z"},"accession":"S-EPMC5652798","cross_references":{"pubmed":["29100407"],"doi":["10.18632/oncotarget.20560"]}}